E

Epicrispr

HealthEpigenetic Editing

Epicrispr is focused on developing epigenetic editing therapies for rare muscle diseases. The company aims to leverage its innovative technology to address unmet medical needs in this niche market. The recent funding will help advance their drug development efforts.

Visit website ↗
Total raised
$90M
tracked to date
Latest round
$90M
Aug 11, 2026

Is this your company?

Claim this profile to get matched with investors who fund Health startups.

Claim this profile →

Funding history

  1. 1
    $90MAug 11, 2026
    Announcement ↗

Epicrispr in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile